Nilsine Partners LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nilsine Partners LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,006 shares of the biopharmaceutical company’s stock after purchasing an additional 27 shares during the quarter. Nilsine Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $717,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in REGN. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.2 %

NASDAQ REGN opened at $686.33 on Wednesday. The stock’s 50-day moving average price is $725.65 and its 200-day moving average price is $933.22. The company has a market capitalization of $75.42 billion, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on REGN shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.